SARS News and Research

RSS

High COVID-19 vaccine effectiveness in Israeli HCP

A study aimed to evaluate the VE against SARS-CoV-2 infection by carrying out a prospective cohort study that included healthcare personnel (HCP) in six hospitals in Israel.

7 Sep 2021

Delta and low vaccination rates projected to cause COVID-19 resurgence in United States

In a new medRxiv* preprint study, a team of researchers led by Cécile Viboud of the National Institute of Health analyzed different models predicting the course of the pandemic in the United States for the rest of 2021.

7 Sep 2021

COVID-19 infection does not appear to affect the lung function of young adults, finds study

COVID-19 infection does not appear to affect the lung function of young adults, according to new research presented at the 'virtual' European Respiratory Society International Congress today (Tuesday).

7 Sep 2021

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

Multiplexed electrochemical sensor platform enables simultaneous detection of SARS-CoV-2 RNA and host antibodies

Scientists from the UK and USA have developed an antifouling nanocomposite-coated multiplexed electrochemical sensor platform that can simultaneously detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and virus-specific antibodies. The platform has shown 100% accuracy in detecting viral RNA and IgG-specific anti-SARS-CoV-2 antibodies. The study is currently available on the medRxiv* preprint server.

6 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

Maternal SARS-CoV-2 vaccination in early-third trimester may optimize neonatal seroprotection

Researchers in Israel have conducted a study showing that vaccinating pregnant women against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) early on in the third trimester may maximize transplacental antibody transfer, potentially helping to prevent severe coronavirus disease 2019 (COVID-19) during infancy.

6 Sep 2021

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Researchers in Australia and Finland have provided important insights into how infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – might affect nervous system circuitries and cause neurologic symptoms.

6 Sep 2021

Study reveals Pfizer/BioNTech and Oxford/AstraZeneca COVID-19 vaccine efficacy and immune response in clinically vulnerable individuals

The current study found that a strong S-antibody response occurs following complete vaccination with two different COVID-19 vaccines.

6 Sep 2021

Researchers uncover underlying metabolic changes that are linked to COVID-19 severity

COVID-19 patients have differing immune responses that lead to disease outcomes ranging from asymptomatic SARS-CoV-2 infection to death.

6 Sep 2021

Increased infectivity and immune evasion drive the spread of Delta SARS-CoV-2 variant

Findings suggest infection control measures against variants will need to continue in the post-vaccination era.

6 Sep 2021

COVID-19 presents a higher risk of blood clots than vaccination

The current study found that people were at a slightly higher than normal risk of blood clots after receiving Oxford-AstraZeneca and Pfizer vaccines.

6 Sep 2021

Patients who contract SARS-CoV-2 Delta variant more likely to be hospitalized than those with Alpha

Recently, researchers found the risk of being hospitalized was two times higher for people with the Delta variant as compared to those with the Alpha variant.

6 Sep 2021

Delta variant has a more diverse repertoire of mutations than other variants

In a paper, nearly 2 million SARS-CoV-2 genomes from around the world were analyzed, finding great diversity within the delta variant that exceeds that observed in the more widely spread alpha variant.

6 Sep 2021

Decreased COVID-19 vaccine efficacy amongst IBS patients receiving anti-TNFα drugs

In a paper recently uploaded to the preprint server medRxiv* by Edelman-Klapper et al., the efficacy of the mRNA vaccine is examined amongst IBD patients and compared with healthy volunteers, finding reduced efficacy amongst those receiving anti-TNFα medication.

6 Sep 2021

mRNA COVID-19 vaccine protection wanes after six months: a wide-scale study of the population of Qatar

In a paper recently uploaded to the preprint server medRxiv* by Chemaitelly et al. (August 27, 2021), the long-term effectiveness of the mRNA vaccines is analyzed amongst the Qatar population. The study observed waning protection against infection around six months post-vaccination but lasting protection from death and hospitalization.

6 Sep 2021

Reduction in infectious SARS-CoV-2 shedding in vaccine breakthrough infections

In a paper recently uploaded to the preprint server medRxiv*, breakthrough infections are compared with infections in immunologically naïve individuals

6 Sep 2021

Is the SARS-CoV-2 Lambda variant more vaccine-resistant than the Delta variant?

Researchers in the USA and China recently published a report in which they discussed the potential factors that confer high infectivity and immune resistance on the Delta and Lambda variants.

6 Sep 2021

Characterization of SARS-CoV-2 viral trajectory

In a study available on the preprint server medRxiv* researchers aimed to characterize early viral shedding in patients with incident infection. Read more here.

6 Sep 2021

Israeli study on viral load, Delta infections, vaccinations and boosters

Scientists from Israel have recently explored the effectiveness of two-dose and three-dose regimens of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine (Pfizer/BioNTech) to reduce viral load in breakthrough infections caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Sep 2021

SARS News and Research

High COVID-19 vaccine effectiveness in Israeli HCP

Delta and low vaccination rates projected to cause COVID-19 resurgence in United States

COVID-19 infection does not appear to affect the lung function of young adults, finds study

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Multiplexed electrochemical sensor platform enables simultaneous detection of SARS-CoV-2 RNA and host antibodies

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Maternal SARS-CoV-2 vaccination in early-third trimester may optimize neonatal seroprotection

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Study reveals Pfizer/BioNTech and Oxford/AstraZeneca COVID-19 vaccine efficacy and immune response in clinically vulnerable individuals

Researchers uncover underlying metabolic changes that are linked to COVID-19 severity

Increased infectivity and immune evasion drive the spread of Delta SARS-CoV-2 variant

COVID-19 presents a higher risk of blood clots than vaccination

Patients who contract SARS-CoV-2 Delta variant more likely to be hospitalized than those with Alpha

Delta variant has a more diverse repertoire of mutations than other variants

Decreased COVID-19 vaccine efficacy amongst IBS patients receiving anti-TNFα drugs

mRNA COVID-19 vaccine protection wanes after six months: a wide-scale study of the population of Qatar

Reduction in infectious SARS-CoV-2 shedding in vaccine breakthrough infections

Is the SARS-CoV-2 Lambda variant more vaccine-resistant than the Delta variant?

Characterization of SARS-CoV-2 viral trajectory

Israeli study on viral load, Delta infections, vaccinations and boosters

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News